ELREXFIO DIN 02543567
Status: Marketed
Holder: PFIZER CANADA ULC
Available to quote
Health Canada record
| Active ingredient(s) | ELRANATAMAB 76 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FX32 ELRANATAMAB |
|---|
| Original market date | 23-Jan-2024 |
|---|
| Current status date | 23-Jan-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ELRANATAMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02543559 | ELREXFIO | PFIZER CANADA ULC | Solution | ELRANATAMAB 44 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 32309 | 2023-12-06 | New Drug Submission (NDS) | |
Request a quote for ELREXFIO
How to read a Canadian DIN record